When the API Does Not Dissolve Easily, the Formulation Has to Think Differently
A pharmaceutical API can be chemically potent and still present a major formulation challenge if it has poor aqueous solubility.
This creates a problem:
The drug may be present, but the body cannot necessarily dissolve and absorb it efficiently enough to achieve the desired exposure.
Poor aqueous solubility is a recognized challenge in pharmaceutical development, and amorphous solid dispersions have become an important formulation strategy for selected poorly water-soluble drugs.
One approach is to change the physical state of the API.
Instead of allowing the drug to remain primarily in a stable crystalline form, the API can be incorporated into a polymer-based amorphous matrix.
That is where spray-dried dispersions (SDDs) and amorphous solid dispersions (ASDs) become important.
And this creates a specialized opportunity for pharmaceutical spray-drying equipment manufacturers.
1. The Commercial Process in One View
The basic concept can be represented as:
Poorly Water-Soluble API
↓
API + Polymer + Suitable Solvent/System
↓
Feed Preparation
↓
Atomization
↓
Rapid Solvent Evaporation
↓
Amorphous API-Polymer Particles
↓
Powder Collection
↓
Downstream Processing
↓
Final Drug Product
The spray dryer therefore sits at the heart of a particle-engineering and formulation process, rather than simply performing conventional moisture removal.
Research on spray-dried solid dispersions shows that rapid solvent evaporation can transform an API-carrier solution into solid API-carrier particles, while the API, carrier, solvent, feed concentration and spray-drying parameters influence the resulting physical structure.
2. What Is an Amorphous Solid Dispersion?
An amorphous solid dispersion is a formulation in which an API is dispersed in an amorphous carrier, commonly involving a polymeric matrix.
The objective can include:
- Improving dissolution
- Increasing apparent solubility
- Supporting supersaturation after dissolution
- Improving the bioavailability potential of selected poorly soluble APIs
- Stabilizing the amorphous drug state
ASDs are widely studied as a strategy for poorly water-soluble drugs, although the final performance depends on the specific drug, polymer, formulation and physical stability of the system.
The important point:
An ASD is not simply a “very fine API powder.”
Its performance depends on the physical state and interaction of the API with the carrier.
3. What Is a Spray-Dried Dispersion?
A spray-dried dispersion is produced when a feed containing the API and one or more formulation components is atomized and dried to form particles.
A simplified process is:
API + Polymer → Solution/Suspension → Atomization → Rapid Drying → SDD Powder
The rapid solvent-removal process can help prevent the API from returning to its equilibrium crystalline state during particle formation.
However, producing an amorphous product is not automatic.
The final state depends on:
- API-polymer compatibility
- Solvent selection
- Feed concentration
- Drug loading
- Atomization
- Drying kinetics
- Droplet size
- Drying-gas conditions
- Particle temperature
- Residual solvent
- Storage conditions
Research specifically identifies these formulation and process variables as important to the physical structure and performance of spray-dried dispersions.
4. Why Poorly Water-Soluble APIs Need Formulation Engineering
For a conventional crystalline API, dissolution can be limited by its crystal lattice as well as its interaction with the surrounding liquid.
An amorphous form can have higher apparent solubility than the corresponding crystalline form, but the amorphous state is also thermodynamically less stable and can recrystallize under unfavorable conditions.
This creates the central formulation challenge:
Improve dissolution without losing physical stability.
The spray dryer therefore becomes part of the solution.
5. Where Does Spray Drying Enter the Pharmaceutical Process?
A simplified ASD manufacturing process can look like:
API Synthesis
↓
Purification
↓
API Characterization
↓
Polymer Selection
↓
Solvent/Formulation Development
↓
API + Polymer Feed
↓
SPRAY DRYING
↓
SDD/ASD Powder
↓
Powder Conditioning / Milling / Sieving
↓
Blending
↓
Tableting / Encapsulation / Other Dosage Form
↓
Finished Pharmaceutical Product
The spray dryer is therefore positioned between formulation development and downstream drug-product manufacturing.
That makes it particularly important during technology transfer and scale-up.
6. The GTI Perspective: This Is Powder Engineering, Not Just Drying
For conventional drying:
Liquid → Remove moisture → Dry material
For spray-dried dispersions:
Formulation → Atomization → Droplet formation → Solvent evaporation → Particle formation → Amorphous structure → Powder properties
That is a much more sophisticated process.
GTI therefore approaches ASD spray drying as a combination of:
Formulation
What API-polymer-solvent system is entering the dryer?
Atomization
How are the droplets being created?
Drying
How rapidly is solvent removed?
Particle Formation
What particle morphology is produced?
Powder Recovery
How efficiently is the powder collected?
Downstream Processing
Can the resulting powder be handled, milled, blended and compressed?
GTI’s pharmaceutical drying portfolio includes spray dryers alongside fluidized-bed, vacuum, tray and belt technologies for customized pharmaceutical applications.
7. Why Spray Drying Is Attractive for ASD Manufacturing
Spray drying offers a particularly useful route because it can transform a suitable liquid feed directly into powder.
GTI describes spray drying as a continuous process that converts pumpable liquids, solutions, slurries and emulsions into dry powders through atomization and rapid drying.
For ASD applications, potential advantages include:
- Direct liquid-to-powder conversion
- Continuous processing
- Rapid solvent evaporation
- Controlled particle formation
- Scalable process architecture
- Ability to process suitable API-polymer solutions
- Potential control over particle size and morphology
- Integration with downstream powder handling
Published pharmaceutical research identifies spray drying as an established technology for manufacturing amorphous solid dispersions and emphasizes its potential from early formulation development through commercial applications.
8. What Goes Into the Spray Dryer?
A typical ASD feed may contain:
API
The poorly water-soluble active pharmaceutical ingredient.
Polymer
Used to form the carrier matrix and help maintain the amorphous state.
Depending on formulation development, pharmaceutical polymers can include systems based on materials such as:
- HPMC
- HPMC-AS
- PVP
- PVP/VA
- Soluplus-type polymers
- Other application-specific polymers
The correct polymer is formulation-specific.
Solvent System
The API and polymer must be suitably dissolved or dispersed before atomization.
Depending on the formulation, the solvent system may be aqueous, organic or mixed.
Optional Functional Excipients
Some formulations may incorporate:
- Surfactants
- Plasticizers
- Stabilizers
- Other formulation aids
These are selected during pharmaceutical development rather than dictated by the dryer.
9. A Simple Example of the Transformation
Imagine a poorly water-soluble API that has limited dissolution in its crystalline form.
The formulation team develops:
API + Polymer + Solvent
The feed enters the spray dryer.
The liquid is atomized into tiny droplets.
Solvent evaporates rapidly.
The polymer solidifies around/disperses the API.
The resulting powder contains the API in an amorphous dispersion within the carrier matrix.
The process therefore changes not only the water content but the physical state and particle structure of the formulation.
That is why ASD spray drying belongs in the category of advanced pharmaceutical particle engineering.
10. The Dryer Parameters That Can Change the Final ASD
A spray dryer cannot be specified only by its evaporation capacity.
For ASD/SDD applications, process parameters can influence the final powder.
Feed Concentration
Changes the amount of solids carried into each droplet.
Drug Loading
Influences particle formation and the ability of the polymer to maintain the desired dispersion.
Feed Rate
Influences residence time and drying conditions.
Atomization
Nozzle or rotary atomization affects droplet size and therefore drying behavior.
Inlet Temperature
Controls the thermal driving force entering the chamber.
Outlet Temperature
Provides an important indication of drying conditions and product exposure.
Drying-Gas Flow
Influences heat and mass transfer.
Solvent Properties
Boiling point, volatility and interaction with API/polymer influence drying.
Chamber Design
Airflow pattern and chamber geometry influence particle trajectories and deposition.
Powder Collection
Cyclone, bag filter or other recovery configuration influences yield and product handling.
Research reviews specifically emphasize the interconnected influence of feed concentration, solvent type, gas flow and spray rate on spray-dried solid-dispersion structure.
11. Product Temperature Is More Important Than Heater Temperature
One of the most misunderstood aspects of spray drying is the difference between:
Drying-air temperature
and
Product temperature.
During evaporation, energy is consumed in removing the volatile phase.
Therefore, the product’s actual thermal exposure depends on:
- Moisture/solvent evaporation
- Droplet size
- Residence time
- Feed composition
- Drying-gas conditions
- Chamber design
This is particularly important for pharmaceutical formulations where excessive thermal exposure could affect API or polymer behavior.
GTI’s spray-dryer engineering approach therefore considers process conditions and product characteristics together rather than selecting a heater temperature in isolation.
12. Amorphous Does Not Automatically Mean Better
This is an important technical and SEO distinction.
An amorphous API may provide a dissolution advantage, but the amorphous state is generally less thermodynamically stable than the crystalline state.
The formulation can therefore face:
Recrystallization
The API may return toward a crystalline state during storage.
Moisture Sensitivity
Water can alter polymer interactions and physical stability.
Phase Separation
API and polymer may separate under unfavorable conditions.
Loss of Supersaturation
The initial dissolution advantage may decrease if the API precipitates from solution.
Research on ASDs identifies physical stability and recrystallization as major formulation considerations.
Therefore:
The goal is not simply to make an API amorphous.
The goal is to develop a stable, reproducible and manufacturable amorphous formulation.
13. What the Spray Dryer Must Deliver
For ASD applications, a successful dryer project may need to target multiple powder characteristics simultaneously.
Particle Size
Important for downstream handling and formulation.
Particle Morphology
Can influence flow, packing and dissolution behavior.
Residual Solvent
Must meet the applicable product specification.
Residual Moisture
Can influence physical stability.
Bulk Density
Important for downstream dosage-form processing.
Flowability
Relevant to feeding, blending and compression.
Powder Recovery
Directly influences manufacturing economics.
Amorphous Content / Physical State
Requires appropriate analytical confirmation.
Chemical Stability
The API must remain within its quality specifications.
14. Spray Dryer vs Hot-Melt Extrusion for ASD
Spray drying is not the only route for manufacturing ASDs.
Another important technology is hot-melt extrusion (HME).
The choice depends on the API and formulation.
| Factor | Spray Drying | Hot-Melt Extrusion |
| Feed | Solution/suspension | Solid/polymer blend |
| Solvent | May be required | Generally solvent-free |
| Thermal exposure | Can be controlled through evaporation | Polymer/API melt processing |
| Thermally sensitive API | Can be advantageous for suitable formulations | May be challenging |
| Particle formation | Direct during drying | Requires downstream milling/pelletizing depending on product |
| Scale-up | Established industrial route | Established industrial route |
| ASD suitability | Strong for suitable API/polymer/solvent systems | Strong for suitable thermally processable systems |
FDA’s 2025 generic-drug science workshop included discussion of ASD products and noted that thermally labile drugs may not be ideal candidates for hot-melt extrusion, while spray drying can be used where suitable solvent-based processing is possible.
The correct choice therefore comes from API properties + polymer properties + formulation + manufacturing strategy.
15. Closed-Cycle Spray Drying for Organic Solvent Systems
Some ASD formulations use organic solvents.
That changes the spray-dryer design significantly.
A conventional open-cycle system may not be appropriate where solvent recovery and inert operation are required.
A solvent-based project may require:
- Closed-loop drying
- Inert gas circulation
- Solvent condensation
- Solvent recovery
- Explosion-protection measures
- Appropriate instrumentation
- Pressure control
- Solvent-compatible materials
- Hazardous-area engineering
GTI’s spray-dryer platform includes configurable closed-loop systems for solvent-based products and explosion-safe designs, subject to project requirements.
For GTI, solvent selection is therefore not just a formulation question.
It is also an equipment-engineering question.
16. Powder Collection Is Part of the ASD Process
Producing the particles is only half the job.
The powder must also be recovered efficiently.
A typical system may include:
Drying Chamber
↓
Primary Powder Separation
↓
Cyclone / Bag Filter
↓
Fine Powder Recovery
↓
Product Collection
↓
Downstream Handling
GTI spray-dryer systems can be configured with cyclones, bag filters and other powder-recovery arrangements depending on the process.
For high-value pharmaceutical materials, powder recovery becomes especially important because even small losses can have significant economic consequences.
17. Why ASD Spray Drying Is a High-Value Application
Consider the difference between:
Bulk industrial drying
and
ASD pharmaceutical spray drying.
A bulk dryer may process hundreds or thousands of kilograms of relatively inexpensive material.
An ASD spray dryer may process a comparatively small quantity of an API that has:
- High value per kilogram
- Significant R&D investment
- Strict quality requirements
- Complex formulation development
- Expensive downstream development
Therefore:
Yield matters.
Powder recovery matters.
Reproducibility matters.
Containment matters.
Process control matters.
Scale-up matters.
This makes ASD spray drying a high-value process-engineering opportunity rather than a commodity drying application.
18. From R&D to Commercial Manufacturing
ASD development often begins at laboratory scale.
A simplified development path can be:
API Screening
↓
Polymer Screening
↓
Solvent Selection
↓
Small-Scale Spray Drying
↓
Analytical Characterization
↓
Formulation Optimization
↓
Pilot Scale
↓
Process Optimization
↓
Scale-Up
↓
Commercial Spray Dryer
The challenge is ensuring that the commercial dryer reproduces the critical characteristics established during development.
Published reviews highlight scale-up and process optimization as important issues in spray-dried ASD manufacturing.
19. What Should Be Characterized Before Scale-Up?
An ASD development program may investigate:
Solid-State Properties
- Amorphous/crystalline state
- Glass transition behavior
- Crystallization tendency
- API-polymer interactions
Powder Properties
- Particle size
- Morphology
- Bulk density
- Flowability
- Moisture
- Residual solvent
Performance
- Dissolution
- Supersaturation
- Precipitation tendency
- Release behavior
Stability
- Physical stability
- Chemical stability
- Moisture sensitivity
- Temperature sensitivity
These analytical results help define the Critical Quality Attributes (CQAs) that the commercial spray-drying process needs to protect.
20. GTI’s ASD Spray-Drying Philosophy
GTI does not approach an ASD project as:
“Tell us the required kg/h and we will give you a spray dryer.”
Instead, the process should begin with:
What API?
What polymer?
What solvent?
What concentration?
What drug loading?
What powder characteristics?
What production capacity?
What residual solvent/moisture?
What product-temperature limitation?
What downstream process?
Only then can the dryer be engineered around the actual formulation.
GTI’s pharmaceutical drying systems are positioned around customized process requirements, controlled moisture/solvent removal and protection of formulation integrity.
21. What Can GTI Engineer for ASD / SDD Applications?
Depending on the formulation and scale, GTI can evaluate:
Pharmaceutical Spray Dryer
For API-polymer liquid feeds requiring direct powder formation.
Closed-Loop Spray Dryer
For suitable organic-solvent formulations where solvent recovery and inert operation are required.
Powder Recovery System
Cyclones, filters and associated collection systems.
Feed Preparation System
Feed tanks, agitation and controlled feeding.
Atomization System
Nozzle or rotary atomization depending on the application.
Automated Process Control
Monitoring and control of relevant:
- Temperatures
- Feed rate
- Gas flow
- Pressure
- Vacuum/pressure conditions where applicable
- Drying parameters
Turnkey Integration
Where required, GTI can consider the spray dryer as part of a broader pharmaceutical process system.
22. What Does the Customer Actually Buy?
For a high-value ASD project, the customer is not really buying:
“A spray dryer.”
The customer is buying a platform capable of producing:
A reproducible pharmaceutical powder with defined characteristics.
That means the equipment value is linked to:
Feed control
Atomization
Drying kinetics
Particle formation
Powder recovery
Process control
Scale-up capability
Product protection
This is where GTI can position itself as a process-engineering partner rather than a standard equipment vendor.
23. Where Are Spray-Dried Dispersions Used?
ASD/SDD technology is primarily associated with pharmaceutical development and manufacturing of poorly water-soluble small-molecule drugs, particularly where conventional formulation approaches do not provide the desired dissolution or exposure characteristics.
Potential applications include:
- Oral drug formulations
- Poorly water-soluble APIs
- Immediate-release formulations
- Selected modified-release development
- Drug-development programs
- Specialty pharmaceutical formulations
- Generic drug development
- Innovative pharmaceutical products
Published reviews describe ASDs as an established approach for poorly water-soluble drugs and discuss applications from pharmaceutical development through clinical and commercial translation.
24. Why This Application Is Important for Pharmaceutical Manufacturers
Modern pharmaceutical development increasingly encounters molecules where conventional crystalline APIs create formulation challenges.
The formulation-development question can become:
“How do we turn a poorly soluble API into a manufacturable dosage form with suitable dissolution performance?”
Possible approaches include:
- Particle-size reduction
- Salt formation
- Co-crystals
- Lipid-based systems
- Nanocrystals
- Amorphous solid dispersions
- Spray-dried dispersions
- Hot-melt extrusion
- Other formulation technologies
ASD is therefore part of a broader solubility-enhancement toolbox, not a universal solution for every API.
That makes equipment suppliers who understand the formulation context particularly valuable.
25. India: A Major Opportunity for ASD Spray Dryers
India’s pharmaceutical manufacturing ecosystem creates a strong geographic market for specialized pharmaceutical spray-drying systems.
A Government of India survey identified 118 pharmaceutical clusters across 19 states/UTs, with Maharashtra, Gujarat, Andhra Pradesh, Himachal Pradesh, Rajasthan, Telangana, Uttar Pradesh, Karnataka and Tamil Nadu among the states containing significant numbers of clusters.
For GTI, the strongest strategy is therefore not simply:
“Spray Dryer Manufacturer India.”
It is:
Application + Technology + Pharmaceutical Cluster + Location
For example:
- ASD Spray Dryer Manufacturer India
- Pharmaceutical Spray Dryer Hyderabad
- API Spray Dryer Gujarat
- Amorphous Solid Dispersion Spray Dryer Maharashtra
- Pharmaceutical Spray Dryer Pune
- SDD Spray Dryer Telangana
- API Polymer Spray Dryer Ahmedabad
26. Maharashtra
The Government of India’s pharma-cluster survey identified 40 pharmaceutical clusters in Maharashtra, the highest number among the states covered in the survey.
Important pharmaceutical manufacturing locations include areas around:
- Mumbai
- Pune
- Aurangabad / Chhatrapati Sambhajinagar
- Thane
- Nashik
- Other industrial pharmaceutical clusters
keywords
Amorphous Solid Dispersion Spray Dryer Maharashtra
Pharmaceutical Spray Dryer Pune
API Spray Dryer Manufacturer Maharashtra
SDD Manufacturing Equipment Mumbai
Pharmaceutical Spray Drying System Aurangabad
27. Gujarat
Gujarat was identified in the government pharma-cluster survey with 13 pharmaceutical clusters.
Relevant pharmaceutical and chemical manufacturing centres include:
- Ahmedabad
- Vadodara
- Ankleshwar
- Vapi
- Dahej
These locations are commercially relevant for equipment searches involving:
- API manufacturing
- Pharmaceutical intermediates
- Specialty chemicals
- Formulation development
- Advanced pharmaceutical processing
keywords
ASD Spray Dryer Manufacturer Gujarat
Pharmaceutical Spray Dryer Ahmedabad
API Spray Dryer Vadodara
Amorphous Solid Dispersion Equipment Ankleshwar
Pharmaceutical Spray Dryer Gujarat
28. Telangana & Hyderabad
The government survey identified 7 pharmaceutical clusters in Telangana.
Hyderabad is therefore a particularly relevant GEO market for advanced pharmaceutical drying.
Potential customer segments include:
- API manufacturers
- Formulation companies
- Pharmaceutical R&D
- Drug-development companies
- Specialty formulation manufacturers
- CDMOs
Target keywords
ASD Spray Dryer Hyderabad
Pharmaceutical Spray Dryer Hyderabad
Amorphous Solid Dispersion Manufacturer Telangana
API Polymer Spray Dryer Hyderabad
Spray Dryer for Poorly Soluble APIs Telangana
29. Andhra Pradesh
The government survey identified 8 pharmaceutical clusters in Andhra Pradesh.
Potential target locations include pharmaceutical manufacturing areas around:
- Visakhapatnam
- Vijayawada
- Other industrial clusters
keywords
Pharmaceutical Spray Dryer Andhra Pradesh
API Spray Dryer Visakhapatnam
ASD Spray Drying System Andhra Pradesh
30. Himachal Pradesh
Himachal Pradesh was identified with 7 pharmaceutical clusters, with Baddi/Solan being particularly important pharmaceutical manufacturing locations.
keywords
Pharmaceutical Spray Dryer Baddi
ASD Spray Dryer Himachal Pradesh
API Spray Dryer Baddi
Pharmaceutical Spray Drying Equipment Solan
31. Karnataka
Karnataka was identified with 5 pharmaceutical clusters in the government survey.
Bengaluru and surrounding areas are also important for pharmaceutical, biotechnology and research activities.
keywords
Pharmaceutical Spray Dryer Bengaluru
ASD Spray Dryer Karnataka
API Spray Dryer Bangalore
Amorphous Solid Dispersion Equipment Bengaluru
32. Tamil Nadu
Tamil Nadu was also identified with 5 pharmaceutical clusters.
Potential target locations include:
- Chennai
- Hosur
- Coimbatore
- Other pharmaceutical/industrial clusters
keywords
Pharmaceutical Spray Dryer Chennai
ASD Spray Dryer Tamil Nadu
API Spray Dryer Chennai
Pharmaceutical Spray Drying System Tamil Nadu
33. Global Markets
ASD and SDD manufacturing is not limited to India.
High-value pharmaceutical markets where advanced formulation and spray-drying capabilities are relevant include:
United States
Strong pharmaceutical R&D, formulation-development and generic/innovative-drug ecosystem.
Germany
Large pharmaceutical and chemical manufacturing base with high demand for advanced process equipment.
Switzerland
Important pharmaceutical and life-science ecosystem.
United Kingdom
Strong pharmaceutical R&D and formulation-development sector.
Belgium & Ireland
Important pharmaceutical manufacturing and European supply-chain locations.
Japan
Advanced pharmaceutical development and manufacturing market.
South Korea
Major biopharmaceutical and pharmaceutical manufacturing ecosystem.
China
Large pharmaceutical manufacturing and formulation-development market.
Singapore
Important Asian pharmaceutical and specialty manufacturing hub.
For GTI, these markets create opportunities for:
Pharmaceutical Spray Dryer
ASD Spray Dryer
Poorly Soluble API
Country/Cluster
This is considerably more commercially targeted than simply competing for the generic keyword “spray dryer.”
34. Why Pharmaceutical Customers Need a Customized Spray Dryer
Two pharmaceutical companies may both manufacture an ASD, but their processes may be completely different.
One may use:
API + HPMC-AS + organic solvent
Another may use:
API + PVP/VA + mixed solvent
Another may use:
API + polymer + aqueous/organic system
Their:
- Feed concentration
- Drug loading
- Viscosity
- Solvent volatility
- Droplet size
- Drying rate
- Powder morphology
- Residual solvent target
may all be different.
Therefore:
One standard spray-dryer specification cannot automatically fit every ASD formulation.
35. The GTI Advantage: Engineering Around the Formulation
GTI’s approach is to connect:
Formulation
→ Feed System
→ Atomization
→ Drying Chamber
→ Powder Separation
→ Collection
→ Downstream Processing
This process-chain approach can help the customer avoid treating the spray dryer as an isolated piece of equipment.
GTI’s spray-drying systems are described as customizable according to product characteristics, capacity and powder-quality objectives, with options including hygienic construction, solvent-based closed-loop systems and automated process control.
36. What GTI Needs Before Designing an ASD Spray Dryer
For a technical discussion, provide as much of the following as possible:
| Parameter | Information |
| API | Product name/type |
| API properties | Solubility / thermal sensitivity |
| Polymer | Type and concentration |
| Drug loading | % w/w |
| Solvent | Water / organic / mixed |
| Feed concentration | % solids |
| Feed rate | kg/h or L/h |
| Viscosity | cP, if available |
| Desired particle size | µm |
| Target residual solvent | Project specification |
| Target moisture | Project specification |
| Powder bulk density | If known |
| Production capacity | kg/day or kg/year |
| Atomization | Existing/preferred, if any |
| Downstream process | Tablet/capsule/etc. |
| Installation | City / country |
| Regulatory requirements | Applicable project requirements |
This allows GTI to evaluate the appropriate spray-dryer configuration rather than quoting a generic machine.
37. Commercial Project Flow
A typical GTI engagement can follow:
01 — Process Discussion
Understand the API, polymer, solvent and target powder.
02 — Feed Evaluation
Determine feed properties and evaporation requirement.
03 — Technology Selection
Evaluate spray-drying architecture and solvent-handling requirements.
04 — Engineering
Develop chamber, atomization, air-handling and collection configuration.
05 — Automation
Define process monitoring and control requirements.
06 — Manufacturing
Fabricate the customized system.
07 — Installation & Commissioning
Support implementation according to project scope.
08 — Scale-Up / Optimization
Where applicable, support process optimization around the selected equipment.
GTI describes its pharmaceutical drying offering as including process design, equipment manufacturing, automation, installation/commissioning support and process optimization.
38. Why This Is a High-Value GTI Application
ASD spray drying combines several high-value engineering requirements:
Pharmaceutical formulation
Solvent handling
Particle engineering
Precision atomization
Thermal control
Powder recovery
Process automation
Scale-up
That creates a very different commercial proposition from selling a generic industrial spray dryer.
The buyer is looking for a system that can support the manufacturability of a pharmaceutical formulation.
39. Frequently Asked Questions
What is a spray-dried dispersion?
A spray-dried dispersion is a dried pharmaceutical formulation produced by spray drying a suitable API-containing feed, often involving a polymeric carrier. For appropriate formulations, the process can generate an amorphous dispersion designed to improve dissolution of poorly water-soluble drugs.
What is an amorphous solid dispersion?
An ASD is a formulation approach in which an API is maintained in an amorphous state within a carrier matrix, commonly a polymer, to improve dissolution/solubility performance for selected poorly water-soluble drugs.
Why is spray drying used for ASDs?
Spray drying can rapidly remove solvent from an API-polymer feed and directly produce solid particles. Its rapid drying and particle-formation characteristics make it a widely studied and established ASD manufacturing route.
Is spray drying the only way to manufacture ASDs?
No. Hot-melt extrusion and other approaches can also be used. The appropriate technology depends on the API, polymer, thermal sensitivity, solvent compatibility and formulation strategy.
What APIs are suitable for ASD spray drying?
Poorly water-soluble small-molecule APIs are the main target, but suitability must be established through formulation development. Solubility alone is not enough to determine whether an API is suitable for spray-dried ASD manufacturing.
Does an amorphous API always remain amorphous?
No. Amorphous systems can recrystallize or undergo phase changes during storage. Polymer selection, formulation composition, residual moisture, temperature and storage conditions all influence physical stability.
Can organic solvents be used in ASD spray drying?
Yes, suitable formulations may use organic or mixed solvents. However, solvent-based spray drying requires appropriate process-safety, condensation, recovery and potentially closed-loop/inert system engineering.
Can GTI manufacture a pharmaceutical ASD spray dryer?
GTI manufactures customized pharmaceutical spray-drying systems and provides spray-dryer configurations for pharmaceutical applications. ASD-specific design should be based on the actual API-polymer-solvent feed, production capacity and powder requirements.
What information is required for ASD spray-dryer sizing?
Important information includes API/polymer composition, drug loading, solvent, feed concentration, feed rate, viscosity, target particle size, residual solvent/moisture, required production capacity and downstream processing requirements.
40. The GTI ASD Spray Dryer Buyer Checklist
Before requesting a quotation, prepare:
API:
What molecule are you processing?
Solubility:
What is the formulation challenge?
Polymer:
Which polymer system has been selected?
Drug Loading:
What percentage of API is required?
Solvent:
Water, organic or mixed?
Feed:
What is the solids concentration and viscosity?
Powder:
What particle size, morphology and bulk density are required?
Quality:
What are the residual moisture and solvent specifications?
Capacity:
Laboratory, pilot or commercial?
Downstream:
Tablet, capsule, sachet or another dosage form?
Location:
Where will the spray dryer be installed?
These inputs allow the equipment design to start from the formulation, not from a generic machine catalogue.
41. Final Commercial Message
A poorly soluble API is a formulation challenge.
An amorphous solid dispersion is a formulation strategy.
A spray dryer is the process-engineering platform that can turn that formulation strategy into a reproducible powder when the formulation and process are suitable.
That requires more than:
Hot Air + Chamber + Nozzle
It requires:
Formulation Understanding
Atomization
Drying Kinetics
Particle Engineering
Powder Recovery
Solvent Management
Automation
Scale-Up
This is where GTI Dryers positions its expertise.
GTI develops customized pharmaceutical spray-drying systems around the API, polymer, solvent, feed properties, required powder characteristics and production capacity.
GTI Dryers — Engineered in India. Designed for the World.
42. Talk to GTI About Your ASD / SDD Spray-Drying Project
Planning a:
Spray-Dried Dispersion
Amorphous Solid Dispersion
Poorly Soluble API Formulation
API + Polymer Spray-Drying Process
Pharmaceutical Powder Manufacturing Project
?
Send GTI:
API + Polymer + Drug Loading + Solvent + Feed Concentration + Feed Rate + Target Particle Size + Residual Solvent/Moisture + Production Capacity + Plant Location
The GTI engineering team can then evaluate the appropriate pharmaceutical spray-drying and powder-recovery configuration for your process.
GTI Dryers
Spray-Dried Dispersion Manufacturer | Amorphous Solid Dispersion Spray Dryer | Pharmaceutical Spray Drying Systems
Engineered in India. Designed for the World.